Sudipto Mukherjee, MD from Cleveland Clinics discusses promising novel agents that can change the treatment landscape and FLT3 and IDH1 inhibitors, luspatercept at the 2017 American Society of Hematology.
Promising Novel Agents That Can Change the Treatment Landscape – FLT3 and IDH1 Inhibitors, Luspatercept
